exhibit 10. 8 certain identified information has been excluded from the exhibit because it is both ( i ) not material and ( ii ) would likely cause competitive harm to the company, if publicly disclosed. double asterisks denote omissions. distributed bio, inc antibody library subscription agreement this antibody library subscription agreement ( “ agreement ” ), effective as of october 11, 2017 ( the “ effective date ” ), is made by and between distributed bio, inc, a california corporation, having offices at 329 oyster point blvd, 3rd floor, south san francisco ca us 94080 ( “ distributed bio ” ) and pandion therapeutics, inc., a delaware corporation, having offices at c / o labcentral, 700 main street, north, cambridge, ma 02139 ( “ subscriber ” or “ client ” ), and sets forth the terms and conditions on which distributed bio will transfer certain materials to subscriber and subscriber ’ s use thereof. distributed bio and subscriber are each referred to herein as a “ party ” or collectively as the “ parties. ” 1. background. distributed bio is willing to transfer the antibody library and other deliverables for use as set forth herein. subscriber desires to obtain the antibody library for the purpose of conducting certain research related to the discovery of antibodies against biological target ( s ) of interest to subscriber and to exercise the rights granted to subscriber herein ( the “ purpose ” ). 2. definitions. an “ agonist ” of an inhibitory receptor is an antibody or other molecule that binds to such inhibitory receptor and induces a biological response, which biological response inhibits or attenuates the activity of the cell bound by such antibody or other molecule. agonists include, without limitation, any antibody or other molecule which may only act as an agonist in a multi - valent format. agonists also include, without limitation, antibodies or other molecules which may act as intrinsic agonists, not requiring a valency of more than one to elicit an agonist effect. agonists include, without limitation, antibodies or other molecules which may act as antagonists in a monovalent format, but as agonists in a multivalent format, dependent on epitope targeted, where an “ antagonist ” of an inhibitory receptor is an antibody or other molecule that prevents such inhibitory receptor from interacting with, and /